Biosimilar is a biologic medical product which is highly similar to another already approved biological medicine.
This report aims to provide a comprehensive presentation of the global market for Adalimumab, Infliximab And Etanercept Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab, Infliximab And Etanercept Biosimilars. This report contains market size and forecasts of Adalimumab, Infliximab And Etanercept Biosimilars in global, including the following market information:
Global Adalimumab, Infliximab And Etanercept Biosimilars Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Adalimumab, Infliximab And Etanercept Biosimilars Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Adalimumab, Infliximab And Etanercept Biosimilars companies in 2022 (%)
The global Adalimumab, Infliximab And Etanercept Biosimilars market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Adalimumab Biosimilars Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Adalimumab, Infliximab And Etanercept Biosimilars include Boehringer Ingelheim, Abbvie, Cipla Ltd, Hetero Drugs Limited, Pfizer, Novartis, Samsung Bioepis(Samsung Biologics), Amgen and Celltrion Healthcare, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adalimumab, Infliximab And Etanercept Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adalimumab, Infliximab And Etanercept Biosimilars Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segment Percentages, by Type, 2022 (%)
Adalimumab Biosimilars
Infliximab Biosimilars
Etanercept Biosimilars
Global Adalimumab, Infliximab And Etanercept Biosimilars Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Adalimumab, Infliximab And Etanercept Biosimilars Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adalimumab, Infliximab And Etanercept Biosimilars revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Adalimumab, Infliximab And Etanercept Biosimilars revenues share in global market, 2022 (%)
Key companies Adalimumab, Infliximab And Etanercept Biosimilars sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Adalimumab, Infliximab And Etanercept Biosimilars sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Boehringer Ingelheim
Abbvie
Cipla Ltd
Hetero Drugs Limited
Pfizer
Novartis
Samsung Bioepis(Samsung Biologics)
Amgen
Celltrion Healthcare
Mylan
HETERO
Glenmark Pharmaceuticals
Emcure Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Adalimumab, Infliximab And Etanercept Biosimilars, market overview.
Chapter 2: Global Adalimumab, Infliximab And Etanercept Biosimilars market size in revenue and volume.
Chapter 3: Detailed analysis of Adalimumab, Infliximab And Etanercept Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Adalimumab, Infliximab And Etanercept Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Adalimumab, Infliximab And Etanercept Biosimilars capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Adalimumab, Infliximab And Etanercept Biosimilars Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Adalimumab, Infliximab And Etanercept Biosimilars Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Adalimumab, Infliximab And Etanercept Biosimilars Overall Market Size
2.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size: 2022 VS 2029
2.2 Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Adalimumab, Infliximab And Etanercept Biosimilars Sales: 2018-2029
3 Company Landscape
3.1 Top Adalimumab, Infliximab And Etanercept Biosimilars Players in Global Market
3.2 Top Global Adalimumab, Infliximab And Etanercept Biosimilars Companies Ranked by Revenue
3.3 Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue by Companies
3.4 Global Adalimumab, Infliximab And Etanercept Biosimilars Sales by Companies
3.5 Global Adalimumab, Infliximab And Etanercept Biosimilars Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Adalimumab, Infliximab And Etanercept Biosimilars Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Adalimumab, Infliximab And Etanercept Biosimilars Product Type
3.8 Tier 1, Tier 2 and Tier 3 Adalimumab, Infliximab And Etanercept Biosimilars Players in Global Market
3.8.1 List of Global Tier 1 Adalimumab, Infliximab And Etanercept Biosimilars Companies
3.8.2 List of Global Tier 2 and Tier 3 Adalimumab, Infliximab And Etanercept Biosimilars Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size Markets, 2022 & 2029
4.1.2 Adalimumab Biosimilars
4.1.3 Infliximab Biosimilars
4.1.4 Etanercept Biosimilars
4.2 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue & Forecasts
4.2.1 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2018-2023
4.2.2 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2024-2029
4.2.3 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2018-2029
4.3 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales & Forecasts
4.3.1 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2018-2023
4.3.2 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2024-2029
4.3.3 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2018-2029
4.4 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2022 & 2029
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Online Pharmacies
5.2 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue & Forecasts
5.2.1 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2018-2023
5.2.2 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2024-2029
5.2.3 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2018-2029
5.3 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales & Forecasts
5.3.1 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2018-2023
5.3.2 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2024-2029
5.3.3 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2018-2029
5.4 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2022 & 2029
6.2 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue & Forecasts
6.2.1 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2018-2023
6.2.2 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2024-2029
6.2.3 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2018-2029
6.3 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales & Forecasts
6.3.1 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2018-2023
6.3.2 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2024-2029
6.3.3 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2018-2029
6.4.2 By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2018-2029
6.4.3 US Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.4.4 Canada Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.4.5 Mexico Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2018-2029
6.5.2 By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2018-2029
6.5.3 Germany Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.5.4 France Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.5.5 U.K. Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.5.6 Italy Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.5.7 Russia Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.5.8 Nordic Countries Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.5.9 Benelux Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2018-2029
6.6.2 By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2018-2029
6.6.3 China Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.6.4 Japan Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.6.5 South Korea Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.6.6 Southeast Asia Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.6.7 India Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2018-2029
6.7.2 By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2018-2029
6.7.3 Brazil Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.7.4 Argentina Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2018-2029
6.8.3 Turkey Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.8.4 Israel Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.8.5 Saudi Arabia Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
6.8.6 UAE Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Boehringer Ingelheim
7.1.1 Boehringer Ingelheim Company Summary
7.1.2 Boehringer Ingelheim Business Overview
7.1.3 Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.1.4 Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.1.5 Boehringer Ingelheim Key News & Latest Developments
7.2 Abbvie
7.2.1 Abbvie Company Summary
7.2.2 Abbvie Business Overview
7.2.3 Abbvie Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.2.4 Abbvie Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.2.5 Abbvie Key News & Latest Developments
7.3 Cipla Ltd
7.3.1 Cipla Ltd Company Summary
7.3.2 Cipla Ltd Business Overview
7.3.3 Cipla Ltd Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.3.4 Cipla Ltd Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.3.5 Cipla Ltd Key News & Latest Developments
7.4 Hetero Drugs Limited
7.4.1 Hetero Drugs Limited Company Summary
7.4.2 Hetero Drugs Limited Business Overview
7.4.3 Hetero Drugs Limited Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.4.4 Hetero Drugs Limited Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.4.5 Hetero Drugs Limited Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.5.4 Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Novartis
7.6.1 Novartis Company Summary
7.6.2 Novartis Business Overview
7.6.3 Novartis Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.6.4 Novartis Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.6.5 Novartis Key News & Latest Developments
7.7 Samsung Bioepis(Samsung Biologics)
7.7.1 Samsung Bioepis(Samsung Biologics) Company Summary
7.7.2 Samsung Bioepis(Samsung Biologics) Business Overview
7.7.3 Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.7.4 Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.7.5 Samsung Bioepis(Samsung Biologics) Key News & Latest Developments
7.8 Amgen
7.8.1 Amgen Company Summary
7.8.2 Amgen Business Overview
7.8.3 Amgen Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.8.4 Amgen Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.8.5 Amgen Key News & Latest Developments
7.9 Celltrion Healthcare
7.9.1 Celltrion Healthcare Company Summary
7.9.2 Celltrion Healthcare Business Overview
7.9.3 Celltrion Healthcare Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.9.4 Celltrion Healthcare Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.9.5 Celltrion Healthcare Key News & Latest Developments
7.10 Mylan
7.10.1 Mylan Company Summary
7.10.2 Mylan Business Overview
7.10.3 Mylan Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.10.4 Mylan Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.10.5 Mylan Key News & Latest Developments
7.11 HETERO
7.11.1 HETERO Company Summary
7.11.2 HETERO Adalimumab, Infliximab And Etanercept Biosimilars Business Overview
7.11.3 HETERO Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.11.4 HETERO Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.11.5 HETERO Key News & Latest Developments
7.12 Glenmark Pharmaceuticals
7.12.1 Glenmark Pharmaceuticals Company Summary
7.12.2 Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Business Overview
7.12.3 Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.12.4 Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.12.5 Glenmark Pharmaceuticals Key News & Latest Developments
7.13 Emcure Pharmaceuticals
7.13.1 Emcure Pharmaceuticals Company Summary
7.13.2 Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Business Overview
7.13.3 Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
7.13.4 Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2018-2023)
7.13.5 Emcure Pharmaceuticals Key News & Latest Developments
8 Global Adalimumab, Infliximab And Etanercept Biosimilars Production Capacity, Analysis
8.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Production Capacity, 2018-2029
8.2 Adalimumab, Infliximab And Etanercept Biosimilars Production Capacity of Key Manufacturers in Global Market
8.3 Global Adalimumab, Infliximab And Etanercept Biosimilars Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Adalimumab, Infliximab And Etanercept Biosimilars Supply Chain Analysis
10.1 Adalimumab, Infliximab And Etanercept Biosimilars Industry Value Chain
10.2 Adalimumab, Infliximab And Etanercept Biosimilars Upstream Market
10.3 Adalimumab, Infliximab And Etanercept Biosimilars Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Adalimumab, Infliximab And Etanercept Biosimilars Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Adalimumab, Infliximab And Etanercept Biosimilars in Global Market
Table 2. Top Adalimumab, Infliximab And Etanercept Biosimilars Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Share by Companies, 2018-2023
Table 5. Global Adalimumab, Infliximab And Etanercept Biosimilars Sales by Companies, (K Units), 2018-2023
Table 6. Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Adalimumab, Infliximab And Etanercept Biosimilars Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Adalimumab, Infliximab And Etanercept Biosimilars Product Type
Table 9. List of Global Tier 1 Adalimumab, Infliximab And Etanercept Biosimilars Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Adalimumab, Infliximab And Etanercept Biosimilars Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2018-2023
Table 15. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2024-2029
Table 16. By Application ? Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2018-2023
Table 20. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2024-2029
Table 21. By Region ? Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2018-2023
Table 25. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2024-2029
Table 26. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2018-2023
Table 29. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2024-2029
Table 30. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2018-2023
Table 33. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2024-2029
Table 34. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2018-2023
Table 37. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2024-2029
Table 38. By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2018-2023
Table 41. By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2024-2029
Table 46. Boehringer Ingelheim Company Summary
Table 47. Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 48. Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Boehringer Ingelheim Key News & Latest Developments
Table 50. Abbvie Company Summary
Table 51. Abbvie Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 52. Abbvie Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Abbvie Key News & Latest Developments
Table 54. Cipla Ltd Company Summary
Table 55. Cipla Ltd Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 56. Cipla Ltd Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Cipla Ltd Key News & Latest Developments
Table 58. Hetero Drugs Limited Company Summary
Table 59. Hetero Drugs Limited Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 60. Hetero Drugs Limited Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Hetero Drugs Limited Key News & Latest Developments
Table 62. Pfizer Company Summary
Table 63. Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 64. Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Pfizer Key News & Latest Developments
Table 66. Novartis Company Summary
Table 67. Novartis Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 68. Novartis Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Novartis Key News & Latest Developments
Table 70. Samsung Bioepis(Samsung Biologics) Company Summary
Table 71. Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 72. Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Samsung Bioepis(Samsung Biologics) Key News & Latest Developments
Table 74. Amgen Company Summary
Table 75. Amgen Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 76. Amgen Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Amgen Key News & Latest Developments
Table 78. Celltrion Healthcare Company Summary
Table 79. Celltrion Healthcare Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 80. Celltrion Healthcare Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Celltrion Healthcare Key News & Latest Developments
Table 82. Mylan Company Summary
Table 83. Mylan Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 84. Mylan Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Mylan Key News & Latest Developments
Table 86. HETERO Company Summary
Table 87. HETERO Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 88. HETERO Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. HETERO Key News & Latest Developments
Table 90. Glenmark Pharmaceuticals Company Summary
Table 91. Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 92. Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Glenmark Pharmaceuticals Key News & Latest Developments
Table 94. Emcure Pharmaceuticals Company Summary
Table 95. Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings
Table 96. Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. Emcure Pharmaceuticals Key News & Latest Developments
Table 98. Adalimumab, Infliximab And Etanercept Biosimilars Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 99. Global Adalimumab, Infliximab And Etanercept Biosimilars Capacity Market Share of Key Manufacturers, 2021-2023
Table 100. Global Adalimumab, Infliximab And Etanercept Biosimilars Production by Region, 2018-2023 (K Units)
Table 101. Global Adalimumab, Infliximab And Etanercept Biosimilars Production by Region, 2024-2029 (K Units)
Table 102. Adalimumab, Infliximab And Etanercept Biosimilars Market Opportunities & Trends in Global Market
Table 103. Adalimumab, Infliximab And Etanercept Biosimilars Market Drivers in Global Market
Table 104. Adalimumab, Infliximab And Etanercept Biosimilars Market Restraints in Global Market
Table 105. Adalimumab, Infliximab And Etanercept Biosimilars Raw Materials
Table 106. Adalimumab, Infliximab And Etanercept Biosimilars Raw Materials Suppliers in Global Market
Table 107. Typical Adalimumab, Infliximab And Etanercept Biosimilars Downstream
Table 108. Adalimumab, Infliximab And Etanercept Biosimilars Downstream Clients in Global Market
Table 109. Adalimumab, Infliximab And Etanercept Biosimilars Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Adalimumab, Infliximab And Etanercept Biosimilars Segment by Type in 2022
Figure 2. Adalimumab, Infliximab And Etanercept Biosimilars Segment by Application in 2022
Figure 3. Global Adalimumab, Infliximab And Etanercept Biosimilars Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2018-2029 (US$, Mn)
Figure 7. Adalimumab, Infliximab And Etanercept Biosimilars Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Adalimumab, Infliximab And Etanercept Biosimilars Revenue in 2022
Figure 9. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2018-2029
Figure 11. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2018-2029
Figure 12. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2018-2029
Figure 15. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2018-2029
Figure 16. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2018-2029
Figure 20. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2018-2029
Figure 21. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2018-2029
Figure 22. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2018-2029
Figure 23. US Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2018-2029
Figure 28. Germany Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 29. France Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2018-2029
Figure 37. China Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 41. India Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2018-2029
Figure 43. By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2018-2029
Figure 44. Brazil Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2018-2029
Figure 48. Turkey Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 52. Global Adalimumab, Infliximab And Etanercept Biosimilars Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Adalimumab, Infliximab And Etanercept Biosimilars by Region, 2022 VS 2029
Figure 54. Adalimumab, Infliximab And Etanercept Biosimilars Industry Value Chain
Figure 55. Marketing Channels
